Search research articles
Contact Us
Filters
Showing results (1-10 of 54) with videos related to
Page
of 6
Sort By:
Leukemia & Lymphoma
|
October 27, 2006
P53 gene alterations identified in classical Hodgkin's lymphoma cell lines
Carl G Maki
Aging
|
July 7, 2010
Decision-making by p53 and mTOR
Carl G Maki
Current Pharmaceutical Design
|
March 12, 2011
Pharmacologic activation of p53 by small-molecule MDM2 antagonists
Hong Shen, Carl G Maki
Journal of Cellular Biochemistry
|
August 31, 2010
p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells
Hong Shen, Carl G Maki
Translational Cancer Research
|
October 3, 2017
The IGF-1R/AKT pathway determines cell fate in response to p53
Lei Duan, Carl G Maki
Translational Lung Cancer Research
|
March 18, 2024
Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer
Lei Duan, Carl G Maki
The Journal of Biological Chemistry
|
May 22, 2010
Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells
Hong Shen, Carl G Maki
Cell Signaling
|
January 13, 2025
Potential biomarkers for MCL1 inhibitor sensitivity
Lei Duan, Carl G Maki
Molecular Cancer Therapeutics
|
April 8, 2010
Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells
Diarmuid M Moran, Carl G Maki
Methods in Molecular Biology (Clifton, N.J.)
|
June 5, 2003
Stability and ubiquitination of the tumor suppressor protein p53
Lesley J Jardine, Carl G Maki
Page
of 6
Search research articles
Search
Showing results (1-10 of 54) with videos related to
Sort By:
Page
of 6
Leukemia & Lymphoma
|
October 27, 2006
P53 gene alterations identified in classical Hodgkin's lymphoma cell lines
Carl G Maki
Aging
|
July 7, 2010
Decision-making by p53 and mTOR
Carl G Maki
Current Pharmaceutical Design
|
March 12, 2011
Pharmacologic activation of p53 by small-molecule MDM2 antagonists
Hong Shen, Carl G Maki
Journal of Cellular Biochemistry
|
August 31, 2010
p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells
Hong Shen, Carl G Maki
Translational Cancer Research
|
October 3, 2017
The IGF-1R/AKT pathway determines cell fate in response to p53
Lei Duan, Carl G Maki
Translational Lung Cancer Research
|
March 18, 2024
Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer
Lei Duan, Carl G Maki
The Journal of Biological Chemistry
|
May 22, 2010
Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells
Hong Shen, Carl G Maki
Cell Signaling
|
January 13, 2025
Potential biomarkers for MCL1 inhibitor sensitivity
Lei Duan, Carl G Maki
Molecular Cancer Therapeutics
|
April 8, 2010
Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells
Diarmuid M Moran, Carl G Maki
Methods in Molecular Biology (Clifton, N.J.)
|
June 5, 2003
Stability and ubiquitination of the tumor suppressor protein p53
Lesley J Jardine, Carl G Maki
Page
of 6